UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended April 30, 2014
	For the quarterly period ended October 31, 2014
[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from __________ to __________
	Commission File Number: 333-176736

~~Remmington Enterprises~~Altovida, Inc.

(Exact name of registrant as specified in its charter)

Nevada	45-2759045
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

BioCity Scotland, Newhouse, Lanarkshire, UK ML1 5UH
(Address of principal executive offices)

+44 1698 53 9797
(Registrant’s telephone number)

_______________________________________________________________
(Former name, former address and former fiscal year, if changed since last report)

Indicated by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [Yes [ ] ~~Yes~~No [X] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

[ ] Large accelerated filer

[ ] Non-accelerated filer

[ ] Accelerated filer

[X] Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ~~[ ] Yes [X] No~~

~~State~~Yes ~~the~~[ ] ~~number~~No ~~of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 15,349,833 common shares as of July 17, 2014.~~[X]

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 77,650,166 as of December 01, 2014.

Table of Contents

	TABLE OF CONTENTS	Page

PART I – FINANCIAL INFORMATION

Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	6
Item 4:	Controls and Procedures	6

PART II – OTHER INFORMATION

Item 1:	Legal Proceedings	7
Item 1A:	Risk Factors	7
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	7
Item 3:	Defaults Upon Senior Securities	7
Item 4:	Mine Safety Disclosures	7
Item 5:	Other Information	7
Item 6:	Exhibits	7

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Our financial statements included in this Form 10-Q are as follows:

F-1	Condensed Consolidated Balance Sheets as of ~~April~~October 3031, 2014 and July 31, ~~2013~~2014 (unaudited);
F-2	Condensed Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~April~~October 3031, 2014 and the period from November 22, 2013 (inception) to July 31, 2014 (unaudited);
F-3	Condensed ~~Statements~~Consolidated Statement of ~~Cash~~Other ~~Flows~~Comprehensive (Loss) for the ~~nine~~period ~~months~~from ~~ended~~November ~~April 30~~22,2013 ~~2014~~(inception) ~~and~~to ~~2013~~October 31, 2014 (unaudited);
F-4	~~Notes~~Condensed Consolidated Statements of Cash Flows for the three months ended October 31, 2014 and the period from November 22, 2013 (inception) to ~~Condensed~~October ~~Financial~~31, ~~Statements.~~2014 (unaudited);
F-5	Notes to Condensed Financial Statements.

These unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended ~~April~~October 3031, 2014 are not necessarily indicative of the results that can be expected for the full year.

Table of Contents

~~Remmington Enterprises~~ALTOVIDA, ~~Inc~~ INC.

Condensed Consolidated Balance ~~Sheets (Unaudited)~~Sheet

	April 30,			July 31,
	2014			2013
ASSETS
Current assets
Cash	$	—		$	811
Total current assets		—			811
Other assets
Capitalized mining claims		—			20,600
Total assets	$	—		$	21,411
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
Current liabilities
Accounts payable and accrued expenses	$	17,778		$	127,621
Note payable		24,435			—
Total current liabilities		42,213			127,621
Stockholders’ (deficit)
Preferred stock, $0.001 par value; 10,000,000 shares authorized, None issued and outstanding at April 30, 2014 and July 31, 2013, respectively		—			—
Common stock, $0.001 par value; 90,000,000 shares authorized, 14,950,000 and 12,900,000 issued and outstanding at April 30, 2014 and July 31, 2013, respectively		14,950			12,900
Additional paid-in capital		40,300			40,300
Subscriptions receivable		(2,050	)		—
Accumulated (deficit)		(95,413	)		(159,410	)
Total stockholders’ (deficit)		(42,213	)		(106,210	)
Total liabilities and stockholders’ (deficit)	$	—		$	21,411

(Unaudited)

The accompanying notes are an integral part of theses financial statements.

	October 31,			July 31,
	2014			2014
ASSETS
Current assets:
Cash	$	33,447		$	210,399
Accounts receivable		50,298			44,508
Prepaid and deposits		17,273			3,381
Inventory		46,806			49,718
Other current assets		13,270			57,402
Total current assets		161,094			365,408
Fixed assets:
Equipment, net of accumulated depreciation of $1,346 and $353, respectively		20,523			20,141
Total assets	$	181,617		$	385,549
LIABILITIES AND STOCKHOLDERS' (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities	$	386,668		$	344,995
Total current liabilities		386,668			344,995
Long term liabilities:
Note payable		445,000			445,000
Total long-term liabilities		445,000			445,000
Total liabilities		831,668			789,995
Stockholders' (deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of October 31, 2014 and July 31, 2014, respectively		—			—
Common stock, $0.001 par value; 90,000,000 shares authorized; 77,650,166 and 89,930,166 issued and outstanding at October 31, 2014 and July 31, 2014, respectively		77,650			89,930
Subscription receivable		(62,300	)		(74,580	)
Additional paid in capital		364,684			364,684
Other comprehensive income		73,392			(10,958	)
Accumulated (deficit)		(1,103,447	)		(773,522	)
Total stockholders' (deficit)		(650,051	)		(404,446	)
Total liabilities and stockholders' deficit	$	181,617		$	385,549

The notes are an integral part to these condensed consolidated financial statements.

F-1

Table of Contents

~~Remmington Enterprises~~ALTOVIDA, ~~Inc~~ INC.

Condensed ~~Statements~~Consolidated Statement of Operations ~~(unaudited)~~

	For the Three Months Ended						For the Nine Months Ended
	April 30,						April 30,
	2014			2013			2014			2013
Revenue	$	—		$	—		$	—		$	—
Operating Expenses:
Professional fees		17,645			13,000			49,850			56,915
General and administrative		17,173			—			24,425			960
Total operating expenses		34,818			13,000			74,275			57,875
(Loss) from operating activities		(34,818	)		(13,000	)		(74,275	)		(57,875	)
Other income:
Gain on sale of asset – related party		—			—			138,271			—
Net income (loss) before income tax provision		(34,818	)		(13,000	)		63,997			(57,875	)
Provision for income taxes		—			—			—			—
Net income (loss)	$	(34,818	)	$	(13,000	)	$	63,997		$	(57,875	)
Net income (loss) per share - basic and diluted	$	(0.00	)	$	(0.00	)	$	0.00		$	(0.00	)
Weighted average number of shares outstanding - Basic and diluted		14,950,000			12,900,000			13,695,971			12,900,000

(unaudited)

The accompanying notes are an integral part of theses financial statements.

	Three Months Ended			November 22, 2013
	October 31,			(Inception) to
	2014			October 31, 2014
Revenue:
Sales income	$	78,952		$	143,865
Cost of sales		38,599			86,067
Gross profit		40,353			57,798
Operating expenses
General and administrative		23,610			112,663
Professional fees		46,144			301,433
Rent expense		30,988			156,380
Research and development		77,907			110,891
Salaries and wages		138,335			436,681
Total operating expenses		316,984			1,118,048
(Loss) from operations		(276,631	)		(1,060,250	)
Other income (expense)
Interest expense		(6,675	)		(12,943	)
Gain on forgiveness of debt		—			24,000
(Loss) on foreign currency transactions		(46,649	)		(54,284	)
Total other income (expense)		(53,324	)		(43,227	)
Net loss	$	(329,955	)	$	(1,103,447	)
Net loss per common share - Basic and diluted	$	(0.00	)	$	(0.05	)
Weighted average shares outstanding - Basic and diluted		84,872,087			22,361,319

The notes are an integral part to these condensed consolidated financial statements.

F-2

Table of Contents

~~Remmington Enterprises~~ALTOVIDA, ~~Inc~~ INC.

Condensed ~~Statements~~Consolidated Statement of ~~cash~~Other ~~flows~~Comprehensive (~~Unaudited~~Loss)

	For the Nine Months Ended
	April 30,
	2014			2013
Cash flows from operating activities:
Net income (loss)	$	63, 997		$	(57,875	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on the sale of mining assets – related party		(138,271	)		—
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		49, 839			49,844
Net cash (used) by operating activities of continuing operations		(24,435	)		(8,031	)
Cash flows from financing activities:
Proceeds from notes payable		24,435			—
Net cash provided by financing activities of continuing operations		24,435			—
Net increase (decrease) in cash		—			(8,031	)
Cash – beginning of period		—			11,642
Cash – end of period	$	—		$	3,611
Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—
Supplemental non-cash information:
Liabilities assumed in connection with sale of mining assets	$	(158,871	)	$	—

(unaudited)

The accompanying notes are an integral part of theses financial statements.

	November 22, 2013
	(Inception) to
	October 31, 2014
Balance, July 31, 2014		(784,480	)
Net (loss)		(329,955	)
Cummulative translation adjustment:
Foreign currency translation		84,350
Total comprehensive (loss)	$	(1,030,085	)

The notes are an integral part to these condensed consolidated financial statements.

F-3

Table of Contents

~~Remmington Enterprises~~ALTOVIDA, ~~Inc~~ INC.

~~Notes~~Condensed toConsolidated ~~Condensed~~Statement ~~Financial~~of ~~Statements~~Cash Flows

(Unaudited)

	Three Months Ended			November 22, 2013
	October 31,			(Inception) to
	2014			October 31, 2014
Cash flows from operating activities
Net (loss)	$	(329,955	)	$	(1,103,447	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		993			1,346
Gain on forgiveness of debt		—			(24,000	)
(Gain) loss on foreign currency transactions		46,649			54,284
Changes in operating assets and liabilities
(Increase) in accounts receivable		(5,790	)		(50,298	)
(Increase) decrease in inventory		2,912			(46,806	)
(Increase) in prepaid expenses		(13,892	)		(17,273	)
(Increase) decrease in other assets		44,132			(13,270	)
Increase in accounts payable and accrued liabilities		79,374			366,806
Net cash used in operating activities		(175,577	)		(832,688	)
Cash flows from investing activities
Purchase of fixed assets		(1,375	)		(21,865	)
Net cash provided by inventing activities		(1,375	)		(21,865	)
Cash flows from financing activities
Proceeds from cash advances		—			50,000
Proceeds from loans payable		—			419,000
Proceeds from the sale of common stock		—			419,000
Net cash provided by financing activities		—			888,000
Net change in cash		(176,952	)		33,447
Cash at beginning of period		210,399			—
Cash at end of period	$	33,447		$	33,447
		—			—
Supplemental cash flow Information:
Cash paid for interest	$	—		$	—
Cash paid for income taxes	$	—		$	—
Supplemental disclosure of non-cash investing and financing activities:
Accounts payable and accrued liabilities assumed through acquisition	$	—		$	45,915

The notes are an integral part to these condensed consolidated financial statements.

F-4

Table of Contents

Altovida, Inc.

Notes To Condensed Consolidated Financial Statements

(unaudited)

~~note~~Note 1 ~~nature~~ - Nature of ~~operations~~Business and ~~summary~~Summary of ~~significant~~Significant ~~accounting~~Accounting ~~policies~~Policies

~~(A)~~ Nature of Operations

~~Remmington Enterprises~~Altovida, Inc. (the "Company") was originally incorporated under the laws of the State of Nevada on July 15, 2011~~. As of~~ ~~January~~as 15Remmington Enterprises, Inc. On May 02 2014, Remmington Enterprises, Inc. isacquired noAltovida ~~longer~~Biosciences inLtd ~~the~~(formerly Mitovie Pharma Europe Ltd) and changed its business offocus ~~precious~~from ~~metal~~the ~~mineral~~mining activities to the pharmaceutical industry. Following the acquisition, the ~~exploration~~Company amended its articles of incorporation to change its name from Remmington Enterprises, Inc. to Altovida, Inc. on October ~~and~~29, ~~development~~2014.

~~During~~Basis ~~January 2014, the Company underwent a significant change in direction. On January 16, 2014 the former CEO and sole director~~ of ~~the~~ Company, Gary Scroggins resigned and immediately was replaced by Hans Morgan Van Niekerk. Simultaneously, the Company assigned all of the assets as well as relinquished assumption of all the obligations as of that date to Mr. Scroggins. Under the new direction of Mr. Van Niekerk, Remmington Enterprises, Inc. is currently evaluating alternative business opportunities.Presentation

~~(B)~~The ~~Basis~~condensed interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by the Company, without audit, pursuant to the rules and regulations of the ~~Presentation~~Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.

~~The~~These ~~accompanying~~statements ~~unaudited~~reflect ~~condensed~~all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these interim financial statements ~~have~~be ~~been~~read ~~prepared~~in conjunction bywith the financial statements of the Company infor ~~accordance~~the ~~with~~period ~~generally~~ended ~~accepted~~July 31, 2014 and notes thereto included in the Company's Form 10-K. The Company follows the same accounting ~~principles~~policies in the ~~United~~preparation ~~States~~ of ~~America~~interim reports.

~~The~~Results ~~accompanying unaudited condensed financial statements contain all adjustments (consisting only~~ of ~~normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position of the Company as of April 30, 2014, and the results of its~~ operations ~~and cash flows~~ for the ~~three~~interim ~~and~~periods nine months ended April 30, 2014. Certain information and footnote disclosures normally included in financial statements have been condensed or omitted pursuant to rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”). The Company believes that the disclosures in the unaudited condensed financial statements are ~~adequate to make the information presented~~ not ~~misleading.~~indicative ~~However,~~of ~~the~~annual unaudited condensed financial statements included herein should be read in conjunction with the financial statements and notes thereto included in the Company’s Form 10-K for the year ended July 31, 2013 filed with the Commission on October 29, 2013results.

The Company has adopted a July 31 year end.

~~(C)~~Principles ~~Use~~ of ~~Estimates~~consolidation

InThe ~~preparing~~consolidated financial statements ininclude ~~conformity with generally accepted accounting principles in~~ the ~~United~~accounts ~~States~~ of ~~America~~Altovida, ~~management is~~Inc. ~~required to make estimates~~ and ~~assumptions~~Altovida ~~that~~Biosciences ~~affect~~Ltd. All ~~the~~significant ~~reported~~intercompany balances ~~amounts of assets~~ and ~~liabilities~~transactions ~~and~~have ~~the~~been ~~disclosure~~eliminated. ~~of contingent~~Altovida, ~~assets~~Inc. and ~~liabilities~~Altovida atBiosciences ~~the~~Ltd ~~date~~will ofbe ~~the~~collectively ~~financial~~referred ~~statements~~herein to ~~and~~as ~~expenses during~~ the ~~reported period~~“Company”. ~~Actual results could differ from those estimates.~~

~~(D)~~Use ~~Cash~~of ~~and Cash Equivalents~~Estimates

The ~~Company~~preparation ~~considers~~of ~~all~~financial ~~highly~~statements ~~liquid~~in ~~temporary~~accordance ~~cash~~with ~~investments~~United ~~with~~States angenerally ~~original~~accepted ~~maturity~~accounting principles requires management to make estimates and assumptions that affect the reported amounts of ~~three~~assets ~~months~~and orliabilities ~~less~~at tothe bedate ~~cash~~of ~~equivalents~~the financial statements and the reported amounts of revenue and expenses in the reporting period. At The Company regularly evaluates estimates and assumptions ~~April~~related 30to stock-based compensation, ~~2014~~and deferred income tax asset valuation allowances. The Company bases its estimates and ~~July~~assumptions on 31current facts, ~~2013~~historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company ~~had~~may $0differ materially and ~~$811~~adversely infrom ~~cash~~the ~~equivalents~~Company’s estimates. To the extent there are material differences between the estimates and the actual results, ~~respectively~~future results of operations will be affected.

~~F-4~~Cash and Cash Equivalents

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At October 31, 2014, the Company had $33,447 in cash and no cash equivalents.

F-5

Table of Contents

~~Remmington~~Note ~~Enterprises,~~1 ~~Inc.~~- Nature of Business and Summary of Significant Accounting Policies (Continued)

~~Notes~~Property toand ~~Condensed Financial Statements~~Equipment

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (~~Unaudited~~generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

~~(E)~~Equipment 3-5 ~~Fair Value of Financial Instruments~~ years

~~Financial~~Furniture ~~instruments~~7 consist of cash, accounts receivable, accounts payable, notes payable and advances payable. Recorded values of cash, receivables, accounts payable and accrued liabilities approximate fair values due to the short maturities of such instruments. Recorded values for notes payable and related liabilities approximate fair values, since their stated or imputed interest rates are commensurate with prevailing market rates for similar obligations.years

~~(F)~~The ~~Earnings~~Company ~~(Loss)~~reviews ~~Per~~the ~~Share~~carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment there were no impairments needed as of October 31, 2014.

The Company reports earnings (loss) per share in accordance with ASC Topic 260-10. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of April 30, 2014, there were no potential common shares underlying warrants or options.Inventory

~~(G)~~Inventories ~~Revenue~~consist ~~Recognition~~of merchandise held for sale in the ordinary course of business, including cost of freight and other miscellaneous acquisition costs, and are stated at the lower of cost, or market value determined on the first-in-first-out basis. The Company records a write-down for inventories, which have become obsolete or are in excess of anticipated demand or net realizable value. The Company performs a detailed review of inventory each period that considers multiple factors including demand forecasts, market conditions, product life cycle status, product development plans and current sales levels. If future demand or market conditions for the Company’s products are less favorable than forecasted or if unforeseen changes negatively affect the utility of the Company’s inventory, it may be required to record additional write-downs, which would negatively affect gross margins in the period when the write-downs are recorded. If actual market conditions are more favorable, the Company may have higher gross margins when products incorporating inventory that were previously written down are sold.

~~The~~Fair ~~Company~~Value ~~currently has not generated revenues. Any future revenues earned, primarily through the sale~~ of ~~extracted~~Financial ~~minerals,~~Instruments will be recognized utilizing the following general revenue recognition criteria: 1) pervasive evidence of an arrangement exists; 2) delivery has occurred; 3) the price to the buyer is fixed or determinable; and 4) collectability is reasonably assured.

~~(H)~~Financial ~~Income~~instruments ~~Taxes~~consist of cash, inventory, prepaid expenses, accounts payable, and notes payable. Recorded values of these instruments approximate their fair values due to the short-term maturities of such instruments. Recorded values for notes payable and related liabilities approximate fair values, since their stated or imputed interest rates are commensurate with prevailing market rates for similar obligations.

F-6

Table of Contents

Note 1 - Nature of Business and Summary of Significant Accounting Policies (Continued)

Earnings (Loss) Per Share

The Company reports earnings (loss) per share in accordance with ASC Topic 260-10. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. As of October 31, 2014, there were no potential common shares underlying warrants or options.

Revenue Recognition

The Company recognized revenue at point of sale of product utilizing the following general revenue recognition criteria: 1) sales order received, and; 2) the price to the buyer is fixed or determinable; and 3) good have been shipped; and 4) collectability is reasonably assured.

Income Taxes

Income taxes are accounted for under the asset and liability method in accordance with ASC Topic 740-10. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When it is considered to be more likely than not that a deferred tax asset will not be realized, a valuation allowance is provided for the excess.

~~(I)~~Foreign ~~New Accounting Standards~~Currency

The Company accounts for foreign currency in accordance with ASC Topic 830 “Foreign Currency” whereby the local currency is the functional currency. Assets and liabilities of the Company’s foreign locations are translated to reporting currency at the rate of exchange existing at the balance sheet date. Income statement amounts are translated at a weighted average monthly exchange rate for each reporting period. The cumulative translation adjustments resulting from changes in exchange rates are included in the consolidated balance sheet as “Other comprehensive income”, a separate component of stockholders’ equity. Transaction gains and losses are included in the consolidated statement of operations. As of October 31, 2014, the Company recorded $84,350 in translation gains related to foreign currency translation.

New Accounting Standards

On June 10, 2014, the Financial Accounting Standards Board (FASB) issued a new accounting statement that reduces some of disclosures and reporting requirements for development stage companies. The change will be in effect for the interim and annual periods beginning after December 15, 2014. As of such date, among other things development stage entities will no longer be required to report inception-to-date information. The company has elected early adoption of this pronouncement and will no longer being reporting inception-to-date information.

F-57

Table of Contents

~~Remmington~~Note ~~Enterprises,~~1 ~~Inc.~~- Nature of Business and Summary of Significant Accounting Policies (Continued)

~~Notes~~There are no other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to ~~Condensed~~have ~~Financial~~a ~~Statements~~material impact on the Company's present or future financial statements.

~~(Unaudited)~~Note 2 - Going Concern

~~Note~~The ~~2 Going~~accompanying ~~Concern~~financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company recorded a net loss of $329,995 for the period of August 01, 2014 to October 31, 2014. These conditions give rise to doubt about the Company’s ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional financing or sale of its common stock as may be required and ultimately to attain profitability per the current business plan.

~~The~~Note ~~accompanying~~3 ~~financial~~- ~~statements~~Business have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has net income from operations of $63,997 during the nine months ended April 30, 2014 and has an accumulated (deficit) of $95,413.Combination

~~These~~On ~~conditions~~May ~~give~~2, ~~rise~~2014, tothe ~~doubt~~Company ~~about~~completed its acquisition of Altovida Biosciences, Ltd. (“Altovida”). In accordance with the terms of the Exchange Agreement, the Company’s ~~ability~~issued to12,280,000 ~~continue~~shares asof aits ~~going~~common ~~concern.~~stock ~~These~~to ~~financial~~the ~~statements~~shareholders doof Altovida ~~not~~in ~~include~~exchange ~~adjustments~~for ~~relating~~all the outstanding stock of Altovida. Due to the ~~recoverability~~change in control and ~~classification~~form of ~~reported~~consideration ~~asset~~given, ~~amounts~~the ortransaction is being accounted for as a recapitalization of Altovida. Whereby Altovida is the ~~amount~~accounting acquirer and ~~classification~~the Company is the legal acquirer. Accordingly, it is the historic financial statements of ~~liabilities~~Altovida ~~that~~retroactively ~~might~~restated begiving ~~necessary~~effect ~~should~~to the accounting recapitalization. There were 15,505,000 shares of the Company’s becommon ~~unable~~stock outstanding before giving effect to ~~continue~~the asstock issuances ain ~~going~~the ~~concern~~exchange. ~~The~~Immediately following the exchange, the Company’s ~~continuation as~~majority ashareholder ~~going~~cancelled ~~concern~~its is12,050,000 shares. ~~dependent~~In ~~upon~~connection ~~its~~with ~~ability~~the toShare ~~obtain~~Exchange ~~additional~~Agreement, ~~financing~~the orCompany ~~sale~~entered ofinto ~~its~~a ~~common~~Lock-Up ~~stock~~Agreement aswith ~~may~~the beacquiring ~~required~~shareholders whereby the Company and ~~ultimately~~the shareholders agree to ~~attain~~a ~~profitability~~one year prohibition on the sales or transfers of common stock held by the shareholders.

Note 3 4 - Related Party Transactions

~~Asset~~Services ~~purchase~~Agreements

On ~~January~~May 152, 2014, the Company ~~entered~~appointed ~~into~~three anofficers ~~Agreement~~ of ~~Conveyance,~~Altovida ~~Transfer~~as officers and ~~Assignment~~directors of ~~Obligations with~~ the Company~~’s sole~~ ~~officer~~ and ~~director.~~assumed ~~Pursuant~~liabilities related to ~~the~~previously ~~Agreement,~~issued ~~the~~compensation ~~Company~~agreements. ~~transferred~~Pursuant ~~all assets related~~ to ~~its~~the ~~mineral~~original ~~exploration business~~agreements, ~~including~~ ~~mining~~effective ~~claims~~as ~~with~~of ~~originally~~March ~~acquired~~1, on2014 ~~July~~provide for ~~26,~~annual ~~2011~~compensation ~~for~~to ~~cash~~each executive of approximately $20167,~~600.~~110 In(£100,000) ~~exchange~~and ~~for~~standard ~~the~~employee ~~assignment~~benefits ofsubject ~~assets,~~to ~~all~~a ~~liabilities~~probationary ~~totalling~~period ~~$158,871,~~of ~~relating~~six-months. toThe term of the ~~former~~agreement ~~mineral~~is ~~exploration~~indefinite ~~business~~but ~~were~~may be cancelled orwith ~~assumed~~six bymonth ~~the~~written ~~sole~~notice ~~officer~~by ~~and~~either ~~director~~party.

Note ~~4 Advance~~5 - Notes payable

~~During~~On ~~the~~May ~~period ended April 30~~1, 2014, the Company ~~received~~entered into a ~~short-term~~Replacement ~~cash~~Promissory ~~advance~~Note ~~for operating expenses~~ in the amount of $24419,~~435 which~~000 iswith ~~non-interest~~Knight ~~bearing~~Financial, ~~and due on demand~~Ltd. ~~In connection with receipt of the advance and~~ (“Knight”) in contemplation of ~~the~~its ~~Company’s~~ May 2, 2014 Share Exchange Agreement~~, the Company entered into a Replacement Promissory note in the amount of $419,000 whereby the holder agreed to forgive the original advance up to $24,000 (See Note 6)~~.

~~Note 5 Stockholders’ (Deficit)~~ F-8

Table of Contents

Note 5 - Notes payable (Continued)

Whereas, Altovida previously issued a Senior Secured Bridge Loan in the principal amount of $81,421 and received a cash advance in the amount of $50,000 of which Knight agreed to forgive $24,000. The new note was issued by the Company for the purpose of reflecting all amounts owed to Knight and to restate the terms of the aforementioned security agreement. The replacement note bears interest at a rate of 6% per annum, matures on May 1, 2018 and is secured by all the assets of the Company.

As of October 31, 2014, the unpaid principle balance totaled $445,000 and accrued interest amounted to $12,943. Additionally the Company recorded interest expense for the three month period in the amount of $6,675.

Note 6 - Stockholders’ Deficit

We are authorized to issue up to 90,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock. The Preferred Stock may be issued in one or more series, with all rights and preferences being determined by the board of directors.

Preferred Stock

The voting rights, rate of dividends preference in relation to other classes or series, and rights in the event of liquidation related to shares of Preferred Stock of any series are determined by the board of directors and may vary from time to time.

F-6

Table of Contents

Remmington Enterprises, Inc.

Notes to Condensed Financial Statements

(Unaudited)

Note 5 Stockholders’ (Deficit) (Continued)

Common Stock

Holders of common stock have voting rights equal to one vote for each share of Common Stock held and are entitled to receive dividends when, and if declared by the board of directors subject to the rights of any Preferred Stock having preference as to dividends. In the event of liquidation or dissolution, subject to the rights of Preferred Stock holders are entitled to share ratably in the Corporations assets. Holders of Common Stock do not have conversion, redemption or preemptive rights.

On ~~January~~May 152, 2014, the Company ~~issued~~sold 2Knight Financial,~~050,000~~ ~~shares~~Ltd. of69,833 ~~its par value~~ common ~~stock~~shares inat ~~exchange for~~ a ~~subscription~~price ~~receivable in the amount~~ of $~~2,050.~~6 Inper ~~addition to the aforementioned sale~~share, onfor ~~January~~a ~~16,~~total ~~2014,~~proceeds ~~the Company’s sole officer and director~~of ~~sold 10~~$419,000~~,000~~. ~~shares~~As of ~~common~~October ~~stock held personally in a private transaction~~31, to2014 the ~~purchaser~~shares ~~and~~were ~~resigned as an officer and director whereby effectuating a change in control of the Company~~unissued.

~~note~~On ~~6 subsequent~~June ~~events~~20, 2014, the Company issued 37,325,083 shares to its CEO, Michael Richard Hawthorne, and 37,325,083 to its Executive Chairman, Vinod Kaushal at $0.001 per share.

InOn ~~accordance~~September ~~with~~23, ~~ASC 855~~2014, ~~management~~the ~~evaluated~~Company ~~all~~cancelled ~~activity~~12,280,000 shares of ~~the~~its ~~Company~~common ~~through~~stock ~~the~~of ~~issue~~which ~~date~~5,800,000 ofrelated to the ~~financial~~issuance ~~statements and~~on ~~concluded~~June ~~that~~20, no2014 ~~other~~to ~~subsequent~~the ~~events~~Company’s ~~have~~CEO, ~~occurred~~Michael ~~that~~Hawthorne, ~~would~~and ~~require~~5,800,000 ~~recognition~~related orto ~~disclosure~~the inissuance ~~the~~on ~~financial~~June ~~statements other~~20, ~~than~~2014 ~~the~~to ~~following:~~its Executive Chairman, Vinod Kaushal.

OnThe ~~May 1, 2014, the Company entered into a Replacement Promissory Note in the amount of~~ $~~419~~64,~~000~~650 ~~with~~due ~~Knight~~for ~~Financial, Ltd. In contemplation of~~ the ~~Company’s~~adjusted ~~Share~~share ~~Exchange~~balance ~~Agreement~~due ~~with~~from ~~Mitovie~~related ~~Pharma~~parties ~~Europe,~~has ~~Ltd.~~not ~~(“Mitovie”).~~been ~~Mitovie~~paid ~~previously~~as ~~issued a Senior Secured Bridge Loan in the principal amount~~ of ~~$81,421~~October ~~of which~~31, ~~$24,435~~2014 ~~was~~and ~~advanced~~remains ~~to the Company during the period ended April 30, 2013. Knight agreed to forgive up to $24,000 of the original note. The Replacement Promissory Note bears interest at~~ a ~~rate of 6% per annum, matures on May 1, 2018 and is unsecured. Additionally, on May 2, 2014, the Company sold Knight Financial,~~subscription ~~Ltd~~receivable. ~~69,833 common shares at a price of $6 per share, for a total transaction value of $418,998.~~

OnNote ~~May~~7 2 2014, the Company completed its acquisition of Mitovie pursuant to the Exchange Agreement, under the terms of which, the shareholders of Mitovie received 12,280,000 shares of the Company’s common stock in exchange for 100% of the outstanding capital stock of Mitovie. The Exchange is being accounted for as a reverse acquisition and recapitalization. Mitovie is the acquirer for accounting purposes and the Company is the issuer. Accordingly, Mitovie’s historical financial statements for periods prior to the acquisition become those of the acquirer retroactively restated for the equivalent number of shares received in the Exchange. The accumulated deficit of Mitovie is carried forward after the acquisition. Operations prior to the Exchange are those of Mitovie. Earnings per share for the period prior to the Exchange are restated to reflect the equivalent number of shares outstanding. There were 15,505,000 shares of the Company’s common stock outstanding before giving effect to the stock issuances in the exchange. Immediately following the exchange, the Company’s majority shareholder cancelled its 12,050,000 shares. In connection with the Share Exchange Agreement, the Company entered into a Lock-Up ~~Agreement~~Subsequent ~~with the acquiring shareholders whereby the Company and~~ Events

~~F-7~~In accordance with ASC 855, management evaluated all activity of the Company through the issue date of the financial statements and concluded that no subsequent events have occurred that would require recognition or disclosure in the financial statements.

~~Remmington Enterprises, Inc.~~F-9

Notes to Condensed Financial Statements

(Unaudited)

Note 6 subsequent events (continued)

the shareholders agree to a one year prohibition on the sales or transfers of common stock held by the shareholders.

On May 2, 2014, the Company appointed three officers of Mitovie as officers and directors of the Company and assumed liabilities related to previously issued compensation agreements as follows:

Services agreement

On March 1, 2014, Mitovie entered into an employment agreement with Ms. Lorna Peers to act in the capacity of the Company’s chief financial officer and director of finance. Pursuant to the terms of the agreement, the Company will pay annual compensation of £100,000 (approximately $167,110), and standard employee benefits subject to a probationary period of six-months. The term of the agreement is indefinite but may be cancelled with six month written notice by either party.

Services agreement

On March 1, 2014, Mitovie entered into an employment agreement with Dr. Michael Hawthorne to act in the capacity of the Company’s chief executive officer and director. Pursuant to the terms of the agreement, the Company will pay annual compensation of £100,000 (approximately $167,110), and standard employee benefits subject to a probationary period of six-months. The term of the agreement is indefinite but may be cancelled with six month written notice by either party.

Services agreement

On March 1, 2014, Mitovie entered into an employment agreement with Mr. Vinod Kaushal to act in the capacity of chairman of the board of directors. Pursuant to the terms of the agreement, the Company will pay annual compensation of £100,000 (approximately $167,110), and standard employee benefits subject to a probationary period of six-months. The term of the agreement is indefinite but may be cancelled with six month written notice by either party.

F-8

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Overview

We ~~were~~are ~~incorporated~~a inrapidly growing biopharmaceutical company focused on the ~~State~~development and commercialization of ~~Nevada~~medicines onin ~~July~~areas ~~15,~~of ~~2011~~real clinical need. ~~Until recently~~Currently, we ~~were~~operate anthrough ~~exploration~~our ~~stage~~wholly-owned ~~mineral~~subsidiary, ~~exploration~~Altovida ~~company with~~Biosciences ~~claims~~Limited based in ~~Hawthorne~~Scotland, ~~Nevada~~UK.

~~Because~~We ofbelieve ~~the difficulties in raising additional funding for that business, on January 15, 2014,~~ we ~~entered~~adopt ~~into~~a anunique ~~Agreement~~approach ofto ~~Conveyance, Transfer~~management ~~and Assignment~~ of ~~Assets and Assumption of Obligations (~~the ~~“Agreement”)~~risks associated with ~~our~~drug ~~former officer and director, Gary A~~development. ~~Scoggins.~~We ~~Pursuant~~do ~~to the Agreement, we transferred all assets related to our mineral exploration business, including our mining claims, to Mr. Scoggins. In exchange for~~ this ~~assignment~~in oftwo assets, Mr. Scoggins agreed to assume and cancel all liabilities relating to our former mineral exploration business. As a result of the Agreement, we are no longer pursuing the mineral exploration business. ways

~~On May~~by ~~2, 2014, we entered into a Share Exchange Agreement (~~the ~~“Exchange Agreement”) with Mitovie Pharma Europe Ltd.,~~sale ~~a privately held company incorporated under the laws~~ of ~~Scotland (“Mitovie”) and the shareholders of Mitovie. As~~ a ~~result~~ ofportfolio ~~the transaction (the “Exchange”), Mitovie became our wholly-owned subsidiary. In accordance with the terms~~ of ~~the~~commercial ~~Exchange~~drugs ~~Agreement,~~which atwe ~~the~~market ~~closing~~predominantly anin ~~aggregate of 12,280,000 shares of our common stock were issued to~~ the ~~holders~~European ~~of Mitovie’s~~markets; ~~common stock in exchange for their shares of Mitovie.~~ and
~~We intend to carry on the business of Mitovie, as~~ our ~~primary line~~ pipeline of ~~business.~~soon ~~We have relocated our principal executive offices~~ to ~~BioCity~~market ~~Scotland,~~drug ~~Newhouse,~~development ~~Lanarkshire ML1 5UH, UK and our telephone number is +44 1698 53 9797. In the near future, we intend to change our name to Altovida Pharma, Inc. to better reflect our new business direction.~~ projects

WeWhilst ~~are now a specialty pharmaceutical company focused on~~ the ~~development and commercialization of medicines in areas of real clinical need. We incorporate soon to market drug development projects and a portfolio of~~ commercial ~~drugs which we market predominantly in the United Kingdom and Europe. Whilst these commercial~~ products offer the opportunity for revenue growth, the main thrust of the business is to complete the development of ~~our~~ high-value projects and commercialize them in the main global markets (initially through partners), with a priority focus on the USA and Europe.

~~Results~~The ofcurrent ~~Operations~~development ~~for~~portfolio ~~the~~includes ~~three~~5 ~~and~~high-value, ~~nine~~relatively ~~months~~low-risk ~~ended~~medicines ~~April~~which ~~30,~~we ~~2014~~are working to bring to market in the US and ~~2013~~Europe within our current planning period.

WeOf ~~have~~these ~~not~~we ~~earned~~have ~~any~~two ~~revenues~~lead ~~since~~projects: ~~our~~ALT022 ~~inception~~and ~~through April 30, 2014~~ALT025. ~~While~~These wemedicines ~~hope~~are toauto-injector ~~achieve~~versions ~~revenues~~of innaloxone (for the ~~near future~~treatment ~~with~~of ~~our~~opioid ~~product~~overdose) ~~offerings,~~and wemidazolam ~~are~~(for ~~presently~~sedation inand the ~~development~~treatment ~~stage~~ of ~~our~~acute ~~business~~seizures), ~~and we can provide no assurance that we will develop viable products or that we will be able to enter into commercial production and generate sufficient sales~~respectively.

WeCost ~~incurred~~from ~~expenses~~initiation into ~~the~~registration ~~amount~~for ofthe ~~$34,818~~development ~~for~~projects ~~the~~is ~~three~~very ~~months~~low ~~ended~~by ~~April~~regular ~~30,~~pharma ~~2014,~~terms. ~~compared~~Time to ~~expenses~~market offor ~~$13,000~~each ~~for~~of the ~~three~~lead ~~months~~projects ~~ended~~is ~~April~~approximately ~~30,~~2.5 ~~2013~~years. WeDuring ~~incurred~~that ~~expenses in the amount of $74~~time,~~275~~ ~~for~~we ~~the~~plan ~~nine~~to ~~months~~engage ~~ended~~in ~~April~~development 30activities, ~~2014,~~compile ~~compared~~regulatory dossiers toand ~~expenses~~submit offor ~~$57,875~~approval ~~for~~to the ~~nine~~regulatory ~~months~~authorities ~~ended April 30~~(e.g., ~~2013.~~the FDA).

WeWork ~~had~~is aprogressing ~~net~~well ~~loss~~in ofour ~~$34,818~~lead ~~for~~projects ~~the~~and ~~three months ended April 30, 2014 compared with $13,000 for the same period ended April 30, 2014. On January 15, 2014,~~ we ~~sold~~believe ~~our mining claims resulting in other income of $138,271 for the nine months ended April 30, 2014~~ that ~~was~~should ~~not~~this ~~experienced~~continue inour ~~prior~~time ~~periods.~~to Wemarket ~~incurred~~expectations ~~net~~will ~~income~~be ~~of $63,997 for the nine months ended April 30, 2014, as~~met. ~~compared~~This ~~with~~is ~~a net loss of $57~~however,~~875~~ ~~for~~dependent ~~the same period ended 2013. We had a net loss of $95,413 from continued and discontinued operations from inception~~ on ~~July~~further ~~15, 2011 through April 30, 2014~~funding.

~~Our~~The ~~losses~~founders ~~are~~have ~~attributable~~so tofar ~~operating~~invested ~~expenses~~$3.4 ~~together~~million ~~with~~in athe ~~lack~~company’s ofpipeline. ~~any~~We ~~revenues.~~will ~~Our~~need ~~expenses~~to ~~during~~raise ~~the~~capital ~~periods~~to ~~reported~~bring ~~consisted~~our development ~~primarily~~product ofportfolio ~~professional~~to ~~fees~~market. We ~~anticipate~~raised roughly $850,000 to commence our ~~operating~~first ~~expenses~~project, ALT022, but will ~~increase~~need asan estimated $10 million in order to commence work on all projects in the pipeline. If we ~~continue~~are ~~with~~unable ~~our~~to ~~new~~raise ~~plan~~these ~~business~~funds, our plan. is to finish our first project and then commence subsequent projects with revenues generated from ALT022.

The commercial product portfolio includes proprietary medicines and recently in-licensed therapies. This is supported by small scale, inexpensive in-house manufacturing which ensures continuity of supply of these critical medicines and favorable product margins.

Table of Contents

Results of Operations for the three months ended October 31, 2014.

Revenues

We had revenues of $78,952 for the three months ended October 31, 2014. Our revenue is growing and we anticipate it will continue to grow, however, we are a development stage company and there is no guarantee that we will be able to successfully execute our business plan and this could have a detrimental impact on revenue. Gross profit for the three months ended October 31, 2014 was $40,353, or 51.1% of revenues.

Operating Expenses

Operating expenses were $316,984 for the three months ended October 31, 2014 these consisted of salaries and wages of $138,335, professional fees of $46,144, rent expenses of $30,988, general and administrative expenses of $23,610 and research and development of $77,907.

Other (Expenses)

During the three moth period we had total other expenses in the amount of $53,324 comprised of interest expense in the amount of $6,675 and a loss on our foreign currency transactions of $46,649. We anticipate interest to remain consistent through out the remainder of the year. Our loss on foreign currency transactions will continue to fluctuate in concert with the foreign exchange rates between the U.S. dollar and the British pound.

We anticipate our operating expenses will increase as we undertake our plan of operations. The increase will be attributable to development, administrative and operating costs associated with our planned activities and the professional fees associated with our reporting obligations under the Securities Exchange Act of 1934. We intend to closely monitor and align our operating costs to our anticipated revenue growth.

We had a net loss of $329,955 for the three months ended October 31, 2014.

Liquidity and Capital Resources

As of ~~April~~October 3031, 2014, we had no current assets ~~and current liabilities~~ of $42161,~~213~~094 ~~consisting entirely of $17,778 in accounts payable~~ and ~~accrued~~current ~~expenses~~liabilities ~~and~~of $24386,~~435 in notes payable~~668. Thus, we had a working capital deficit of $42225,~~213~~574 as of ~~April~~October 3031, 2014.

OnOperating ~~May~~activities 2,used ~~2014~~$175,577 ~~we sold a promissory note~~ in ~~the~~cash ~~principal~~for ~~amount of $419,000 (~~the ~~“Note”).~~three ~~The~~months ~~Note~~ended ~~accrue~~October ~~interest at the rate of 6% per annum and is due and payable on the earlier of (i) the fourth anniversary of the date of the Note~~31, ~~(ii) upon~~2014. ~~the~~Our ~~occurrence~~negative ofoperating ~~fundraising~~cash offlow atfor ~~least $8,400,000,~~ the ~~sale of assets or change of control, or (iii) when, upon or after~~period ~~the~~was ~~occurrence~~mainly ofa anresult ~~event~~ of ~~default, such amounts are declared due and payable by the holder or made automatically due and payable in accordance with the terms of the Note. Also on May 2, 2014, we sold 69,833 shares of~~ our ~~common~~net ~~stock~~loss ~~to an accredited investor at $6.00 per share~~ for ~~total~~the ~~proceeds of $418,998~~period.

~~Based~~Investing ~~upon~~activities ~~our current financial condition, we have sufficient cash to operate our business at the current level~~ for the ~~next~~three ~~twelve~~ months. ~~For~~ended ~~the~~October ~~long term~~31, we2014 ~~hope~~used ~~to generate sufficient revenues to be self-sustaining. We may~~$1,375 ~~however,~~for ~~require capital to fund our operations in~~ the ~~long~~purchase ~~term if revenues are insufficient. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation~~ of ~~our~~fixed ~~business plan will be impaired~~assets. ~~There can be no assurance that such additional financing will be available to us on acceptable terms or at all.~~

There were no financing activities in the three month period to October 31, 2014.

The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We had net ~~income~~(loss) from operations of $63276,~~997~~631 and a total net (loss) of $329,955 during the ~~nine~~ three months ended ~~April~~October 3031, 2014 and had an accumulated (deficit) of $951,~~413~~103,477.

These conditions give rise to doubt about our ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our continuation as a going concern is dependent upon its ability to obtain additional financing or sale of our common stock as may be required and ultimately to attain profitability.

Off Balance Sheet Arrangements

As of ~~April~~October 3031, 2014, there were no off balance sheet arrangements.

Table of Contents

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Currently, we do not believe that any accounting policies fit this definition.

Recently Issued Accounting Pronouncements

On June 10, 2014, the Financial Accounting Standards Board (FASB) issued a new accounting statement that reduces some of disclosures and reporting requirements for development stage companies. The change will be in effect for the interim and annual periods beginning after December 15, 2014. As of such date, among other things development stage entities will no longer be required to report inception-to-date information. We have elected early adoption of this pronouncement and will no longer being reporting inception-to-date information.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

WeDisclosure ~~carried~~Controls ~~out an evaluation of the effectiveness of the design~~ and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of April 30, 2014. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer, Michael Richard Hawthorne and Chief Financial Officer, Lorna Peers. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of April 30, 2014, our disclosure controls and procedures are not effective. There have been no changes in our internal controls over financial reporting during the quarter ended April 30, 2014.Procedures

~~Management~~We ~~determined~~carried ~~that~~out an evaluation of the ~~material~~effectiveness ~~weaknesses~~of ~~that~~the ~~resulted~~design inand ~~controls~~operation ~~being~~of ~~ineffective~~our ~~are~~disclosure ~~primarily~~controls ~~due~~and toprocedures ~~lack~~(as ofdefined in ~~resources~~Exchange Act Rules 13a-15(e) and ~~number~~ 15d-15(e)) as of ~~employees~~October 31, 2014. ~~Material~~This ~~weaknesses~~evaluation ~~exist~~was incarried out under the ~~segregation~~supervision ofand with ~~duties~~the ~~required~~participation ~~for~~of ~~effective~~our ~~controls~~Chief Executive Officer and ~~various~~our ~~reconciliation~~Chief Financial Officer. Based upon that evaluation our Chief Executive Officer and ~~control~~Chief ~~procedures~~Financial ~~not~~Officer ~~regularly~~concluded ~~performed~~that, as of October 31 2014, our disclosure controls and procedures were not effective due to the ~~lack~~presence of ~~staff~~material ~~and~~weaknesses ~~resources~~in internal control over financial reporting.

~~Disclosure~~A ~~controls~~material ~~and~~weakness ~~procedures~~is ~~are~~a ~~controls~~deficiency, ~~and~~or ~~other~~a ~~procedures~~combination ~~that~~of ~~are~~deficiencies, ~~designed~~in tointernal ~~ensure~~control ~~that~~over ~~information~~financial ~~required~~reporting, tosuch bethat ~~disclosed~~there inis ~~our~~a ~~reports~~reasonable ~~filed~~possibility orthat ~~submitted~~a ~~under~~material misstatement of the ~~Exchange~~company’s ~~Act~~annual ~~are~~or ~~recorded,~~interim ~~processed,~~financial ~~summarized~~statements ~~and~~will ~~reported,~~not be ~~within~~prevented ~~the~~or ~~time~~detected ~~periods specified~~on ina timely basis. Management has identified the ~~SEC's~~following ~~rules~~material ~~and~~weaknesses ~~forms.~~which ~~Disclosure~~have ~~controls~~caused ~~and~~management to ~~procedures~~conclude ~~include~~that, ~~without~~as ~~limitation~~of October 31, 2014, our disclosure controls and procedures ~~designed~~ towere ~~ensure~~not ~~that~~effective: ~~information~~(i) ~~required~~inadequate tosegregation of beduties ~~disclosed~~and ineffective ~~our~~risk ~~reports~~assessment; ~~filed~~and ~~under~~(ii) ~~the~~insufficient ~~Exchange~~written ~~Act~~policies isand ~~accumulated~~procedures ~~and~~for ~~communicated to~~accounting ~~management,~~and ~~including~~financial ~~our~~reporting with ~~Chief~~respect ~~Executive~~to ~~Officer~~the requirements and ~~Chief~~application ~~Financial~~of ~~Officer,~~both toUS ~~allow~~GAAP ~~timely~~and ~~decisions~~SEC ~~regarding required disclosure~~guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending July 31, 2015: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended October 31, 2014 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Internal Controls

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the internal control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A: Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

OnThere ~~May~~have 2,been ~~2014,~~no weissuances ~~sold 69,833 shares~~ of ~~our~~securities ~~common~~without ~~stock~~registration tounder anthe ~~accredited~~Securities ~~investor~~Act atof ~~$6.00~~1933 ~~per~~during ~~share~~the ~~for~~reporting ~~total proceeds of $418,998~~period.

On May 2, 2014, we completed the acquisition of Mitovie pursuant to the Exchange Agreement, under the terms of which, the shareholders of Mitovie received 12,280,000 shares of our common stock in exchange for 100% of the outstanding capital stock of Mitovie.

The shares were issued pursuant to the exemption from registration found in Regulation S, promulgated under the Securities Act of 1933, as amended.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended October 31, 2014 formatted in Extensible Business Reporting Language (XBRL).
	**Provided herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Remmington Enterprises, Inc.
	Altovida, Inc.
Date:	~~July~~December 2112, 2014
By:	/s/ Michael Richard Hawthorne Michael Richard Hawthorne
Title:	Chief Executive Officer and Director

Filing Compare · Altovida Inc.